Yissum - Research Development Company of the Hebrew University

A Novel Therapeutic Approach Targeting Coronavirus Replication-Essential RNAs by Oligonucleotides

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

A Novel Therapeutic Approach Targeting Coronavirus Replication-Essential RNAs by Oligonucleotides
Project ID : 47-2020-10912

Yissum - Research Development Company of the Hebrew University

Description of the technology

The research team plans to develop a drug to inhibit human SARS-CoV-2 replication. They will use comparative genomics to detect conserved regions within the coronavirus family, and within human CoV-19 population, in order to identify essential genes that can be targeted to inhibit the virus replication.

The drug will be a relevant allele-specific oligonucleotide (ASOs), to be delivered into the lung epithelial cells. Following delivery into lung cells, the ASOs will bind the virus’ essential mRNAs, activate RNAse and induce degradation of these mRNAs, and inhibit replication of the virus in the cells.

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Rotem Karni
HUJI, School of Medicine - IMRIC
Biochemistry and Molecular Biology

Yuval Tabach
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research

Alexander Rouvinski
HUJI, School of Medicine - IMRIC
Microbiology and Molecular Genetics

Related keywords

  • Biological Sciences
  • Infectious Diseases
  • Virus, Virology / Antibiotics / Bacteriology
  • Covid-19
  • Genetic Engineering / Molecular Biology
  • Recombinant DNA
  • Industrial genetic engineering applications
  • covid-19

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.